Key result
A dose of slow release oxprenolol produced a significant reduction in exercise-induced tachycardia lasting at least 14 hours, compared to 8 hours for an dose of conventional oxprenolol.
Why the study?
Does slow release oxprenolol provide longer-lasting plasma concentrations and reduction in exercise-induced tachycardia compared to conventional oxprenolol in healthy volunteers?
RCT (n=6)
Does slow release oxprenolol provide longer-lasting plasma concentrations and reduction in exercise-induced tachycardia compared to conventional oxprenolol in healthy volunteers?
Slow release oxprenolol provides a longer duration of action in reducing exercise-induced tachycardia compared to conventional oxprenolol.
Answers are grounded in this paper and cite their sources.
May support once-daily oxprenolol dosing; leaves open translation to clinical outcomes in patients.
1 Plasma concentrations of oxprenolol have been compared in six healthy volunteers after 80 and 160 mg doses of a new slow release (SR) oxprenolol preparation, after an 80 ng dose of conventional oxprenolol (CO), and after the second of two 80 mg doses of conventional oxprenolol given 12 h apart. Basal pulse rates and blood pressures, and pulse rates before and after a standard exercise test have been compared after the four active treatments and after a placebo. 2 Peak plasma concentrations of oxprenolol attained after 160 mg of the slow release preparation were similar to the peak concentrations after the single 80 mg dose of conventional oxprenolol. Higher concentrations, however, persisted for much longer after the slow release preparations than after the conventional preparations. 3 Neither oxprenolol formulation had any effect on resting pulse rate or blood pressure in normotensive volunteers. 4 Comparison with placebo showed that the single dose of the conventional oxprenolol produced a significant reduction in exercise induced tachycardia for 8 h whereas the high dose of the slow release preparation produced a similar reduction which lasted for at least 14 hours.
No takes yet. Share an insight, caveat, or question.
West et al. (1976) conducted an RCT in Healthy volunteers (n=6). Slow release oxprenolol vs. Conventional oxprenolol (80 mg) and placebo was evaluated on Exercise induced tachycardia. A dose of slow release oxprenolol produced a significant reduction in exercise-induced tachycardia lasting at least 14 hours, compared to 8 hours for an dose of conventional oxprenolol.
Synapse has enriched 10 related papers. Consider them for comparative context: